UMediC Group Berhad
UMediC Group Berhad, an investment holding company, develops, manufactures, markets, and distributes medical devices and consumables in Malaysia, the Asia Pacific, the Americas, Europe, the Middle East, Africa, and Oceania. The company operates nursing homes and healthcare centers, and other related services; markets and distributes laboratory equipment and consumables; and provides after-sales s… Read more
UMediC Group Berhad (0256) - Net Assets
Latest net assets as of October 2025: RM83.20 Million MYR
Based on the latest financial reports, UMediC Group Berhad (0256) has net assets worth RM83.20 Million MYR as of October 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (RM94.93 Million) and total liabilities (RM11.72 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | RM83.20 Million |
| % of Total Assets | 87.65% |
| Annual Growth Rate | 65.11% |
| 5-Year Change | 416.9% |
| 10-Year Change | N/A |
| Growth Volatility | 89.01 |
UMediC Group Berhad - Net Assets Trend (2020–2025)
This chart illustrates how UMediC Group Berhad's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for UMediC Group Berhad (2020–2025)
The table below shows the annual net assets of UMediC Group Berhad from 2020 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-07-31 | RM81.35 Million | +11.79% |
| 2024-07-31 | RM72.77 Million | +14.65% |
| 2023-07-31 | RM63.48 Million | +20.50% |
| 2022-07-31 | RM52.68 Million | +234.71% |
| 2021-07-31 | RM15.74 Million | +137.32% |
| 2020-07-31 | RM6.63 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to UMediC Group Berhad's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1038.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (July 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | RM42.62 Million | 53.20% |
| Other Components | RM37.50 Million | 46.80% |
| Total Equity | RM80.12 Million | 100.00% |
UMediC Group Berhad Competitors by Market Cap
The table below lists competitors of UMediC Group Berhad ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pool Advista Indonesia Tbk
JK:POOL
|
$6.96 Million |
|
Curative Biotechnology Inc
NYSE MKT:CUBT
|
$6.96 Million |
|
Indomobil Multi Jasa Tbk
JK:IMJS
|
$6.96 Million |
|
Electro-Sensors Inc
NASDAQ:ELSE
|
$6.96 Million |
|
ADVFN Plc
PINK:AVFCF
|
$6.96 Million |
|
NeuroMetrix Inc
NASDAQ:NURO
|
$6.95 Million |
|
IERVOLINO ENTERTAINMENT
F:G37
|
$6.95 Million |
|
Thai Nam Plastic Public Company Limited
BK:TNPC
|
$6.95 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in UMediC Group Berhad's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 71,984,674 to 80,118,000, a change of 8,133,326 (11.3%).
- Net income of 8,133,578 contributed positively to equity growth.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | RM8.13 Million | +10.15% |
| Other Changes | RM-252.00 | -0.0% |
| Total Change | RM- | 11.30% |
Book Value vs Market Value Analysis
This analysis compares UMediC Group Berhad's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.45x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 17.48x to 1.45x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-07-31 | RM0.02 | RM0.31 | x |
| 2021-07-31 | RM0.04 | RM0.31 | x |
| 2022-07-31 | RM0.14 | RM0.31 | x |
| 2023-07-31 | RM0.17 | RM0.31 | x |
| 2024-07-31 | RM0.19 | RM0.31 | x |
| 2025-07-31 | RM0.21 | RM0.31 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently UMediC Group Berhad utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.15%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.75%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 1.14x
- Recent ROE (10.15%) is below the historical average (20.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 36.47% | 10.22% | 0.79x | 4.51x | RM1.76 Million |
| 2021 | 32.32% | 14.91% | 0.68x | 3.17x | RM3.51 Million |
| 2022 | 12.20% | 12.67% | 0.74x | 1.31x | RM1.16 Million |
| 2023 | 16.38% | 22.70% | 0.62x | 1.16x | RM4.02 Million |
| 2024 | 12.49% | 16.48% | 0.66x | 1.15x | RM1.79 Million |
| 2025 | 10.15% | 16.75% | 0.53x | 1.14x | RM121.78K |
Industry Comparison
This section compares UMediC Group Berhad's net assets metrics with peer companies in the Medical Devices industry.
No peer company data available for comparison.